A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Latest Information Update: 10 Jun 2025
At a glance
- Drugs BI 3031185 (Primary)
- Indications Attention-deficit hyperactivity disorder; Personality disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 10 Jun 2025 New trial record